Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

被引：0
|
作者：
Shen, Qian [1 ]
Gao, Qiqi [2 ]
Zhou, Jianying [1 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Thorac Dis Ctr,Dept Resp Dis, Hangzhou 310003, Zhejiang, Peoples R China
[2] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China
来源：
CHINESE MEDICAL JOURNAL | 2023年 / 136卷 / 07期
关键词：
D O I：
10.1097/CM9.0000000000002403
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：851 / 853
页数：3
相关论文
共 50 条
  • [31] A review of perioperative treatment strategies with immunotherapy and tyrosine kinase inhibitors in resectable and stage IIIA-N2 non-small cell lung cancer
    Hopson, Madeleine B.
    Rashdan, Sawsan
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [32] Adjuvant therapy in stage IIIA-N2 non-small cell lung cancer after neoadjuvant concurrent chemoradiotherapy followed by surgery
    Shin, Sumin
    Kim, Hong Kwan
    Cho, Jong Ho
    Choi, Yong Soo
    Kim, Kwhanmien
    Kim, Jhingook
    Zo, Jae Ill
    Sun, Jong-Mu
    Ahn, Myung-Ju
    Park, Keunchil
    Pyo, Hongryull
    Ahn, Yong Chan
    Shim, Young Mog
    JOURNAL OF THORACIC DISEASE, 2020, 12 (05) : 2602 - 2613
  • [33] Generalized or personalized treatment for stage IIIA-N2 non-small-cell lung cancer?
    Vansteenkiste, Johan
    Van Damme, Valerie
    Dooms, Christophe
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (10) : 1605 - 1609
  • [34] Impact of N2 Extent and Nodal Response on Survival after Trimodal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer
    Kim, Hong Kwan
    Cho, Jong Ho
    Choi, Yong Soo
    Zo, Jae Ill
    Shim, Young Mog
    Park, Keunchil
    Ahn, Myung-Ju
    Ahn, Jin Seok
    Ahn, Yong Chan
    Pyo, Hong Ryull
    Han, Joungho
    Kim, Hojoong
    Kim, Jhingook
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S874 - S874
  • [35] Pathological complete response to neoadjuvant ceritinib of a crizotinib-resistant, stage IIIB non-small cell lung cancer with ALK rearrangement: A case report
    Bing, Zhongxing
    Jia, Ziqi
    Wang, Yadong
    Xue, Jianchao
    Cao, Lei
    Cao, Zhili
    Liu, Peng
    Li, Ji
    Liang, Naixin
    Li, Shanqing
    THORACIC CANCER, 2021, 12 (14) : 2130 - 2133
  • [36] Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma
    Tian, Cuimeng
    Liu, Guimei
    Xu, Yongxiang
    Xia, Guangrong
    Zhang, Tongmei
    Huang, Jiaqiang
    Jiang, Hui
    Wang, Ji Ming
    Li, Baolan
    RADIOLOGY AND ONCOLOGY, 2021, 55 (01) : 66 - 76
  • [37] Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer
    Serritella, Anthony, V
    Bestvina, Christine M.
    THORACIC SURGERY CLINICS, 2020, 30 (02) : 137 - 146
  • [38] Treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer: update and perspectives
    Ryser, Christoph Oliver
    Diebold, Joachim
    Gautschi, Oliver
    CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 8 - 12
  • [39] Paclitaxel and carboplatin as neoadjuvant chemotherapy in operable (stage I and II) and locally advanced (stage IIIA-N2) non-small cell lung cancer
    Splinter, TAW
    SEMINARS IN ONCOLOGY, 1996, 23 (06) : 59 - 61
  • [40] A nomogram to predict the survival of stage IIIA-N2 non-small cell lung cancer after surgery
    Mao, Qixing
    Xia, Wenjie
    Dong, Gaochao
    Chen, Shuqi
    Wang, Anpeng
    Jin, Guangfu
    Jiang, Feng
    Xu, Lin
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2018, 155 (04): : 1784 - +
12345